Abstract
As the use of depot medroxyprogesterone acetate (DMPA) contraception increases in the United States and worldwide, assessing any impact on the risk of breast and gynecologic cancers becomes increasingly important. Overall, use of DMPA does not affect breast cancer risk. An elevated risk of this disease, however, has been noted in recent or current users. Hence, the association between DMPA use and breast cancer risk appears similar to that observed with oral contraceptives. Use of DMPA is associated with an 80% risk reduction of endometrial adenocarcinoma, a level of protection even greater than that noted with oral contraceptives. The risk of epithelial ovarian cancer and cervical neoplasia does not appear to be affected by DMPA use. Except for a substantial reduction in the risk of endometrial adenocarcinoma, use of DMPA does not appear to influence reproductive tract cancer risks.
TY - JOUR
T1 - Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
A1 - Kaunitz,A M,
PY - 1996/5/1/pubmed
PY - 1996/5/1/medline
PY - 1996/5/1/entrez
KW - Americas
KW - Biology
KW - Breast Cancer
KW - Cancer
KW - Case Control Studies
KW - Central America
KW - Cervical Cancer
KW - Contraception
KW - Contraceptive Agents
KW - Contraceptive Agents, Female
KW - Contraceptive Agents, Progestin
KW - Contraceptive Methods
KW - Costa Rica
KW - Depo-provera
KW - Developed Countries
KW - Developing Countries
KW - Diseases
KW - Endometrial Cancer
KW - Family Planning
KW - Injectables
KW - International Agencies
KW - Latin America
KW - Literature Review
KW - Medroxyprogesterone Acetate
KW - Neoplasms
KW - New Zealand
KW - North America
KW - Northern America
KW - Oceania
KW - Organizations
KW - Ovarian Cancer
KW - Recommendations
KW - Research Methodology
KW - Risk Factors
KW - Studies
KW - Un
KW - United States
KW - Who
SP - 419
EP - 27
JF - The Journal of reproductive medicine
JO - J Reprod Med
VL - 41
IS - 5 Suppl
N2 - As the use of depot medroxyprogesterone acetate (DMPA) contraception increases in the United States and worldwide, assessing any impact on the risk of breast and gynecologic cancers becomes increasingly important. Overall, use of DMPA does not affect breast cancer risk. An elevated risk of this disease, however, has been noted in recent or current users. Hence, the association between DMPA use and breast cancer risk appears similar to that observed with oral contraceptives. Use of DMPA is associated with an 80% risk reduction of endometrial adenocarcinoma, a level of protection even greater than that noted with oral contraceptives. The risk of epithelial ovarian cancer and cervical neoplasia does not appear to be affected by DMPA use. Except for a substantial reduction in the risk of endometrial adenocarcinoma, use of DMPA does not appear to influence reproductive tract cancer risks.
SN - 0024-7758
UR - https://www.unboundmedicine.com/medline/citation/8725705/Depot_medroxyprogesterone_acetate_contraception_and_the_risk_of_breast_and_gynecologic_cancer_
L2 - https://www.diseaseinfosearch.org/result/960
DB - PRIME
DP - Unbound Medicine
ER -
